Our solutions span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.
End-to-end services, operational model and technology to deliver customised solutions.
Optimising real world data to drive effective outcomes and achieve regulatory authorisation.
ICON provides its full range of clinical, consulting and commercial services across several industry sectors.
Developing transformative therapies requires a flexible approach.
Partners making a difference.
A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.
ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
Establishing a platform for improvement
Using human-enabled AI to enhance decision-making and minimise risk.
Options for biotech to maximise their funds and improve their asset development program.
ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.
17 June 2024
09 July 2024
Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.
ICON CARES is our commitment to making a positive impact on our people, environment and our community.
Clinical Research. Evolved.
56:50
A drug's propensity to cause QT prolongation has to be carefully evaluated in the course of clinical development, and until recently, regulators have required a designated study, the thorough QT (TQT) study, to rule out a small QT effect. It has howe
1:00:02
48:56
45:28
